Dr. Haskali graduated with a PhD in radiopharmaceutical sciences from the University of Melbourne and then joined the Investigational Medicinal Products (IMP) team at Cyclotek Pty. Ltd. (Jan 2013 – Sep 2014), a Good Manufacturing Practice (GMP) laboratory for the production of Therapeutics Goods Australia (TGA) licensed radiopharmaceuticals. He then furthered his academic and clinical expertise in the development of radiopharmaceuticals for PET imaging at the National Institute of Mental Health (NIMH) in the USA (Oct 2014 – Sep 2016). From Oct 2016, he joined Peter MacCallum Cancer Centre (PMCC) as a senior radiopharmaceutical scientist.
Dr. Haskali currently leads the clinical provision of theranostic radiopharmaceuticals at PMCC. He also leads a research program in radiopharmaceutical sciences with research activities encompassing all aspects of the discipline including i) developing new methods for radiolabelling bioactive molecules, ii) design and synthesis of new radiotracers/theranostics for PET imaging and radionuclide therapy, and iii) clinical provision of radiopharmaceuticals. Dr. Haskali is a certified radiopharmaceutical scientist by the Australasian College of Physical Scientists and Engineers in Medicine (ACPSEM) in their A1 limited category, and have formally established his laboratory as a nationally recognised centre for radiopharmaceutical science training. He currently sits on the professional standards board (PSB) of the ACSPEM as the national representative of radiopharmaceutical sciences in Australia.